Avadel Pharmaceuticals plc (ADR)
General ticker "AVDL" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.1B (TTM average)
Avadel Pharmaceuticals plc (ADR) follows the US Stock Market performance with the rate: 51.0%.
Estimated limits based on current volatility of 1.6%: low 20.96$, high 21.52$
Factors to consider:
- Total employees count: 188 as of 2024
- Top business risk factors: Manufacturing risks, Geopolitical risks, Labor/talent shortage/retention, Expansion risks, Regulatory and compliance
- Current price 46.0% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.30$, 14.63$]
- 2025-12-31 to 2026-12-31 estimated range: [5.15$, 12.15$]
Financial Metrics affecting the AVDL estimates:
- Negative: with PPE of -19.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -4.76 <= 0.33
- Positive: 41.86 < Shareholder equity ratio, % of 44.96 <= 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 5.25 > -0.66
- Positive: Inventory ratio change, % of -16.36 <= -0.75
- Positive: Industry inventory ratio change (median), % of -1.41 <= -0.15
Short-term AVDL quotes
Long-term AVDL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $27.96MM | $169.12MM |
| Operating Expenses | $98.56MM | $165.81MM | $211.52MM |
| Operating Income | $-98.56MM | $-137.85MM | $-42.40MM |
| Non-Operating Income | $-12.88MM | $-22.93MM | $-6.68MM |
| Interest Expense | $12.34MM | $9.89MM | $10.83MM |
| R&D Expense | $20.70MM | $13.26MM | $15.20MM |
| Income(Loss) | $-111.44MM | $-160.78MM | $-49.08MM |
| Taxes | $26.02MM | $-0.50MM | $-0.25MM |
| Profit(Loss)* | $-137.46MM | $-160.28MM | $-48.83MM |
| Stockholders Equity | $-21.14MM | $87.74MM | $73.85MM |
| Inventory | $0.00MM | $10.38MM | $20.30MM |
| Assets | $132.78MM | $164.70MM | $164.24MM |
| Operating Cash Flow | $-70.30MM | $-128.51MM | $-46.91MM |
| Capital expenditure | $0.72MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $79.70MM | $-50.09MM | $51.78MM |
| Financing Cash Flow | $14.54MM | $135.34MM | $15.97MM |
| Earnings Per Share** | $-2.29 | $-2.00 | $-0.51 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.